Clinical Trial Update: Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluated the combination of durvalumab and tremelimumab before surgery in hormone receptor-positive, HER2-negative stage II–III breast can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2022-02-17